Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2020 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2020 First-Quarter Financial Results, Host Conference Call on February 12th

MIAMI, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of...
January 21, 2020 08:30 ET | Source: Veru Inc.

Veru Announces Acceptance of Two Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2020

MIAMI , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of...
January 13, 2020 08:00 ET | Source: Veru Inc.

Veru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy

-- Plans to Advance Zuclomiphene into Pivotal Phase 3 Clinical Trial in First Half of 2020 -- -- Potential to be First FDA-Approved Drug for ADT Induced Hot Flashes -- MIAMI, Jan. 13, 2020 ...
December 12, 2019 06:30 ET | Source: Veru Inc.

Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147%

--Update on Ongoing Phase 1b/2 VERU-111, Oral Selective Antitubulin, Clinical Trial Demonstrates Antitumor Activity and No Dose Related Toxicity Reached in Men with Metastatic Castration Resistant...
December 05, 2019 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 12th

MIAMI, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of...
October 02, 2019 06:30 ET | Source: Veru Inc.

Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes

-- Potential to be First FDA-Approved Drug for ADT induced Hot Flashes – -- Topline Clinical Data Anticipated Fall 2019 -- MIAMI, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU),...
August 28, 2019 08:30 ET | Source: Veru Inc.

Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York

MIAMI, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
August 27, 2019 08:30 ET | Source: Veru Inc.

Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month

MIAMI, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
August 08, 2019 06:30 ET | Source: Veru Inc.

Veru Reports Higher Net Revenues and Gross Profit for its Fiscal 2019 Third Quarter

Promising Clinical Observations for Both Advancing VERU-111 and Zuclomiphene Prostate Cancer Clinical Trials Added VERU-100, Novel First GnRH Antagonist 3 Month Depot Formulation for Androgen...
August 01, 2019 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2019 Third-Quarter Financial Results; Host Conference Call on August 8th

MIAMI, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...